Aug 05, 2024

•

Jun 30, 2024

Theravance Q2 2024 Earnings Report

Reported financial and operational results for the second quarter of 2024.

Key Takeaways

Theravance Biopharma's YUPELRI net sales decreased 1% from the prior quarter. The company is exploring opportunities to unlock value from its Irish tax assets. Patent litigation is pending against four companies.

YUPELRI net sales decreased 1% from the prior quarter.

CYPRESS study enrollment is expected to complete in mid-2025.

TRELEGY had an exceptional quarter.

Exploring opportunities to unlock value from Irish tax assets.

Total Revenue

$14.3M

Previous year: $13.7M

+3.7%

EPS

-$0.13

Previous year: -$0.13

+0.0%

YUPELRI U.S. Net Sales

$54.5M

TRELEGY Global Net Sales

$1.06B

Gross Profit

$4.3M

Previous year: $12.4M

Theravance

Unlock previous datapoints

Upgrade

Theravance

Unlock previous datapoints

Upgrade

Revenue by Segment

YUPELRI Revenue

CapyFin.com

Revenue by Geographic Location

United States Revenue

CapyFin.com

Historical Earnings Impact

Analyze how earnings announcements historically affect stock price performance

Avg. Return Before/After Earnings

Loading earnings performance data...

Loading earnings reaction data...

Company Overview

Full financial data and analysis

View Theravance

Products

Get in Touch

Resources

Theravance Q2 2024 Earnings Report

Key Takeaways

Theravance

Theravance

Revenue by Segment

YUPELRI Revenue

Revenue by Geographic Location

United States Revenue

Historical Earnings Impact

Avg. Return Before/After Earnings

Company Overview

Theravance Revenue by Segment

Theravance Revenue by Geographic Location